Clinical Trial

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-29; most recent amendment 2025-07-18.
Status change: Not Yet Recruiting → Recruiting 2024-02-22
Trial Details
NCT Number NCT06024824
Lead Sponsor Cancer Trials Ireland
Conditions Pancreatic Adenocarcinoma
Enrollment 49 participants
Start Date 2024-01-30
Primary Completion 2027-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-20